BriefCase vs Brainomix 360 e-CTA

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

BriefCase

by Aidoc Medical

Brainomix 360 e-CTA

by Brainomix Limited

AI Verdict

Aidoc's BriefCase is a broader AI-powered communication and collaboration platform for critical medical imaging findings across various pathologies, including stroke. Brainomix 360 e-CTA, while also AI-powered and integrated into a larger platform, is specifically focused on automating and standardizing the assessment of collaterals and detecting large vessel occlusions on CT angiography scans for acute stroke patients. Therefore, while both operate in the medical imaging AI space and have overlap in stroke detection, BriefCase offers a wider range of critical finding detections and communication features, whereas e-CTA provides specialized, in-depth analysis for stroke cases.

Choose BriefCase if…

Choose BriefCase if your primary need is a comprehensive, AI-powered communication and collaboration solution for streamlining the sharing of critical medical imaging findings across various specialties within a large hospital or health system. It excels at prioritizing urgent cases like intracranial hemorrhages, pulmonary embolisms, and brain aneurysms, and ensuring timely communication and follow-up across the care team, ultimately reducing turnaround times and improving patient outcomes.

View BriefCase →

Choose Brainomix 360 e-CTA if…

Choose Brainomix 360 e-CTA if your focus is on specialized, AI-driven analysis of CT angiography scans specifically for acute stroke patients. This tool is ideal for automating and standardizing the assessment of collaterals and detecting large vessel occlusions, providing critical insights for faster and more confident treatment decisions in stroke care.

View Brainomix 360 e-CTA →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	BriefCase	Brainomix 360 e-CTA
Pricing	Enterprise	Contact vendor
Deployment	Cloud	Cloud service (EU and US) and on-site server within the hospital network.
BAA Available	Yes AI-estimated	Unknown
FDA Status	Cleared AI-estimated	1 AI-estimated
HIPAA	Yes AI-estimated	Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

BriefCase

Aidoc's BriefCase offers a more comprehensive communication and collaboration solution, integrating with PACS, RIS, and EHR systems, and providing mobile access for care teams. Brainomix 360 e-CTA focuses primarily on automated image analysis and result delivery, with mobile access for viewing but less emphasis on collaborative features. Aidoc's broader feature set for communication and workflow streamlining suggests a higher degree of usability for diverse care team needs.

Clinical Value

BriefCase

Aidoc's BriefCase, as part of the Aidoc platform, is FDA-cleared for multiple pathologies beyond stroke, including PE, ICH, and C-spine fracture, offering broader clinical utility. Brainomix 360 e-CTA is specialized for acute stroke, focusing on collateral assessment and LVO detection. While both are clinically validated, Aidoc's wider range of cleared algorithms provides value across more clinical scenarios.

Pricing & Value

Tie

Both tools utilize an enterprise pricing model, requiring direct contact with the vendor for specific details, which limits transparency. Aidoc's pricing is estimated to start around $50,000 per site per year, with additional module fees. Brainomix also offers individual modules or packages, but no specific pricing is publicly available.

Enterprise Readiness

BriefCase

Aidoc's BriefCase is designed for large hospitals and health systems, with over 500 global customers and robust compliance certifications (HIPAA, SOC2, GDPR, FDA cleared). Brainomix also offers cloud and on-site deployment and mentions HIPAA adherence, but Aidoc's larger customer base and explicit certifications suggest a more proven enterprise readiness.

Innovation

BriefCase

Aidoc has recently secured FDA clearance for a comprehensive foundation model AI, covering 14 acute indications with improved signal quality and reduced false alerts, demonstrating a significant leap in AI technology. Brainomix 360 e-CTA offers advanced automated assessment for stroke imaging, but Aidoc's foundation model approach represents a broader, more innovative technological advancement.

Support & Docs

Tie

Both companies provide support resources. Brainomix offers FAQs and user manuals through its website. Aidoc, as a larger company with a broader deployment, can be inferred to have comprehensive support and documentation, though specific details are not explicitly provided for BriefCase alone. Without more specific comparative information, it's difficult to definitively pick a winner.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	BriefCase	Brainomix 360 e-CTA
Name	BriefCase	Brainomix 360 e-CTA
Company	Aidoc Medical	Brainomix Limited
Description	FDA-cleared AI-powered communication and collaboration solution integrated into the Aidoc platform, designed to streamline the sharing of critical medical imaging findings among care teams.	AI-powered module within the Brainomix 360 Stroke platform that automates and standardizes the assessment of collaterals and detects large vessel occlusions on CT angiography scans for acute stroke patients.
Key Features	AI-driven critical finding detection (via Aidoc platform), Secure, real-time communication of findings, Customizable communication protocols, Automated follow-up tracking and reminders, Seamless integration with PACS, RIS, and EHR systems, Comprehensive audit trails for all communications, Prioritization of urgent cases for immediate attention, Mobile access for care team collaboration	Automated collateral assessment on CTA scans, Computation of CTA Collateral Score (CTA-CS), Automatic Large Vessel Occlusion (LVO) detection, Indication of CTA acquisition phase for quality control, Multi-planar reconstructions (MPRs) with coronal, sagittal, and axial viewing, Integration within Brainomix 360 Stroke platform, DICOM results sent automatically to PACS or other radiology systems, Email result notifications
Specialties	Cardiology, Emergency Medicine, Neurology, Pulmonology, Radiology	Emergency Medicine, Neurology, Radiology
Mobile App	both	Not specified
Target Size	Large hospitals and health systems	Not specified

Videos

Demos, reviews, and walkthroughs featuring BriefCase and Brainomix 360 e-CTA.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing physician workflows and EHR systems?

BriefCase is designed for seamless integration with PACS, RIS, and EHR systems, offering a comprehensive patient profile by connecting with existing EHR, worklist, and PACS systems. It aims to reduce cognitive load with just-in-time alerting and role-based views. Brainomix 360 e-CTA integrates within the broader Brainomix 360 Stroke platform, delivering results to PACS, mobile app, email, or web UI within minutes of a scan. It also offers secure messaging and calling for care team coordination directly from its mobile app.

What are the reported accuracy and sensitivity of each tool for their respective clinical applications?

Aidoc's BriefCase, across 11 indications, achieved a mean sensitivity of 97% (up to 98.5%) and a mean specificity of 98% (up to 99.7%) in an FDA-reviewed pivotal study. For intracranial hemorrhage detection, Aidoc demonstrated an 85.7% sensitivity and 96.8% specificity in a real-world study. Brainomix 360 e-CTA for large vessel occlusion (LVO) detection has shown a diagnostic accuracy of 91.5% in one study and 72-76% in another large-scale independent test when compared to expert interpretation. Its automated assistance for CTA collateral scoring significantly increased mean accuracy from 58.6% to 67.5%.

What is the typical learning curve for physicians adopting these AI tools?

While specific data on the learning curve isn't provided for either tool, Aidoc's BriefCase emphasizes reducing cognitive load with just-in-time alerting and role-based views, suggesting an intuitive design. Brainomix 360 e-CTA aims to provide helpful decision support, improving scoring accuracy and reading efficiency for physicians across a range of experience, implying a design that facilitates adoption.

What kind of customer support can physicians expect, and how does it impact time-to-value?

Aidoc has a global presence with over 500 hospitals as customers, suggesting a well-established support infrastructure. Aidoc's focus on seamless integration and efficient workflows, including mobile access and automated follow-up tracking, aims to expedite critical information delivery and decision-making, which directly contributes to faster time-to-value. Brainomix has deployed its solutions across 20+ countries and offers user manuals and direct contact for support, indicating a commitment to customer assistance. Their system is designed for rapid processing and delivery of results within minutes, which can quickly demonstrate value in acute stroke settings.

Beyond HIPAA, what additional security measures do these tools employ to protect patient data?

Aidoc's platform runs on AWS and Azure, implementing best-of-breed solutions like EDR, encryption, SIEM, and CSPM, and adheres to the NIST Cybersecurity Framework (CSF). They prioritize anonymization at the source, minimal data collection, and end-to-end encryption, along with continuous monitoring and incident response. Brainomix adheres to GDPR and operates in the US, implying robust data protection strategies. While specific details beyond GDPR and implied HIPAA adherence are not provided, their cloud service and on-site server deployment options suggest flexible security architectures.

Are there audit-trail features available to track AI-assisted decisions and communications?

BriefCase offers comprehensive audit trails for all communications, ensuring traceability of critical medical imaging findings shared among care teams. Brainomix 360 e-CTA, as part of the Brainomix 360 Stroke platform, aims to standardize analysis and support faster treatment decisions, which typically necessitates robust logging for clinical governance, though specific audit trail features are not detailed in the provided information.

What are the considerations for rolling out these tools across multiple hospital sites or a large health system?

Aidoc's BriefCase is designed for large hospitals and health systems, with over 500 global customers, indicating experience with multi-site rollouts. Its enterprise pricing model is customized based on hospital size and deployment, suggesting scalability. Aidoc's aiOSu2122 is built to sustain AI performance and impact at foundation-model scale through data normalization, continuous performance monitoring, and built-in governance, enabling health systems to deploy and manage multi-condition clinical AI without re-architecting infrastructure. Brainomix 360 e-CTA is deployed across 20+ countries, from regional hospitals to leading academic centers, demonstrating its capability for multi-site implementation. The Brainomix 360 Vantage analytics dashboard provides real-time visibility on how the system is performing across a network, monitoring outcomes and clinician engagement across every site and modality.